No. As of September 2026, CG Oncology Inc. (CGON) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones Islamic, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.05% / 30% · (Cash+Inv) / Mkt Cap (36m) 15.9% / 30% · Interest income / Revenue 400.4% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.05% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 15.9% / 33% · Receivables / Mkt Cap (36m) 0.01% / 49% · Interest income / Revenue 400.4% / 5% | Fail |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 0.05% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 15.9% / 33.33% · Receivables / Mkt Cap (24m) 0.01% / 33.33% · Interest income / Revenue 400.4% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.30% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 94.4% / 33.33% · Receivables / Avg Assets (4Q) 0.08% / 33.33% · Interest income / Revenue 400.4% / 5% | Fail |
| FTSE | Debt / Total Assets 0.29% / 33.33% · (Cash+ST Inv) / Total Assets 94.1% / 33.33% · (Cash+Recv) / Total Assets 94.1% / 33.33% · Interest income / Revenue 400.4% / 5% | Fail |
No. As of September 2026, CG Oncology Inc. (CGON) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones Islamic, MSCI and FTSE).
No. CG Oncology Inc. is over the AAOIFI limit on Interest income / Revenue.
About 400.4% of each dividend: CG Oncology Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
CG Oncology Inc. (NASDAQ: CGON) is a Healthcare company (Biotechnology) with a market capitalization of $7.1B. The Maz Rating grades it against the other companies in its sector.
CG Oncology Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $78.95, CG Oncology Inc. trades at 1228.1x sales and 7.6x book value. Over the last twelve months it generated about $6M of revenue and a net loss of $230M. It runs a gross margin of -102.2%, an operating margin of -4293.5% and a net margin of -3851.1%. It shows return on equity of -24.6%, return on invested capital of -26.4% and a free cash flow yield of -2.5%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 21.70. Over the past 52 weeks the share price ranged from $37.01 to $93.95, with a beta of 0.24.
CG Oncology Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 11 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.